Prostate-Specific Membrane Antigen Expression in Meningioma: A Promising Theranostic Target
Open Access
- 30 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology and Experimental Neurology
- Vol. 81 (12), 1008-1017
- https://doi.org/10.1093/jnen/nlac089
Abstract
Meningioma is the most common intracranial neoplasm, yet there is no effective therapy for recurrent/refractory meningiomas after surgery and radiation. Prostate-specific membrane antigen (PSMA) is an enzyme upregulated on endothelial cells of multiple neoplasms and is being investigated as a theranostic target. Until now, PSMA has not been studied in meningiomas. We aimed to verify PSMA endothelial expression in meningiomas, detect tumor grade variability, and investigate the relationship of PSMA signal with tumor recurrence. We analyzed 96 archival meningiomas including 58 de novo and 38 recurrent specimens. All specimens were stained routinely and immunostained for CD31 and PSMA. Slides were scanned and analyzed producing raw data for images of PSMA, CD31, PSMA/CD31, and PSMA/vasculature. PSMA expression was seen within 98.9% of meningioma samples. In the total cohort, higher-grade tumors had increased expression of raw PSMA and PSMA/CD31, and PSMA/vasculature ratios compared to grade 1 tumors. PSMA expression and PSMA/vasculature ratios (p = 0.0015) were higher in recurrent versus de novo tumors among paired samples. ROC curves demonstrated PSMA/CD31, PSMA/vasculature, and raw CD31 as indicators of tumor recurrence. Thus, PSMA is expressed within endothelial cells of meningiomas, is increased with tumor grade and recurrence, and persists with prior irradiation.Keywords
This publication has 31 references indexed in Scilit:
- Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastasesCancer Cell International, 2014
- The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of researchUrologic Oncology, 2013
- Architecture of the Subendothelial Elastic Fibers of Small Blood Vessels and Variations in Vascular Type and SizeMicroscopy and Microanalysis, 2013
- Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma MultiformeArchives of Pathology & Laboratory Medicine, 2011
- Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid TumorsClinical Cancer Research, 2007
- Vascular Targeted Therapy With Anti–Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid TumorsJournal of Clinical Oncology, 2007
- The Mitosis-Specific Antibody Anti-Phosphohistone-H3 (PHH3) Facilitates Rapid Reliable Grading of Meningiomas According to WHO 2000 CriteriaThe American Journal of Surgical Pathology, 2004
- Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2004
- Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.1999
- The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.1998